Terms of Use

NO WARRANTY
Information accessed through this web site is presented in summary and interactive form and is not exhaustive. Sepracor Inc. and its U.S. subsidiaries and affiliates (together, the "Company") make no warranties or representations as to its accuracy or completeness. This information is provided "as is" without warranty of any kind, either express or implied, including but not limited to implied warranties of merchantability, fitness for particular purpose, or non-infringement. Some jurisdictions do not allow exclusion of implied warranties so the above exclusion may not apply to you. Certain links on this site lead to sites or sources located on servers maintained by third parties over which Company has no control. Company makes no representation as to the accuracy or any other aspect of the information contained in or on such sites, sources or servers, nor does Company necessarily endorse such sites or sources. Neither Company nor its affiliates or their respective employees shall be liable in any way for any legal claims, whether in contract, tort or otherwise in any way connected with the use or performance of this web site or any information linked or referenced by this site or any other information or Internet site which link to this site.

The information included in (or accessible from) this web site may contain forward-looking statements that involve risks and uncertainties, including statements with respect to the safety, efficacy, potential benefits, and successful development of the Company's pharmaceuticals under development. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the submission, acceptance, and approval of regulatory filings; the results of clinical trials with respect to products under development; the scope of the Company's patent protection with respect to such product candidates; the commercial success of Company's products; the ability of the company to attract and retain qualified personnel; the performance of Company's licensees; the availability of sufficient funds to continue research and development efforts; and certain other factors that may affect future operating results and are detailed in any periodic reports filed with the Securities and Exchange Commission.

NON-COMMERCIAL USE
Company gives you permission to copy pages of [insert name of website] documents published herein on the Internet for non-commercial use only, provided any copy of these documents that you make shall retain all copyright and other proprietary notices and any disclaimers contained herein.

COPYRIGHTS/TRADEMARKS
All images, trademarks and text are the property of Company and may not be downloaded, distributed, sorted, reused, reported, modified or otherwise used except as provided herein, without the express written permission of Company. All product and service names appearing in a typeface different from that of the surrounding text or with a trademark symbol, including the "Sepracor" logo, are trademarks and service marks owned by Sepracor Inc. or its subsidiaries or affiliates or another company. Use of these marks, except as permitted herein, is expressly prohibited. Nothing contained herein shall be construed as conferring, by implication, estoppel or otherwise, any license or right under any patent or trademark of Company or any third party. Except as expressly provided above, nothing contained herein shall be construed as conferring any license or right under any Company copyright.

NO CONFIDENTIALITY
No confidential relationship shall be established in the event that any user of this Internet site should make any oral, written or electronic response to Company (such as feedback, questions, comments, suggestions, ideas, etc.). Such response and any information submitted therewith shall be considered non-confidential, and Company shall be free to reproduce, publish or otherwise use such information for any purposes whatsoever including, without limitation, the research, development, manufacture, use or sale of products incorporating such information. The sender of any information to Company is fully responsible for its content, including its truthfulness and accuracy and its non-infringement of any other person's proprietary rights.

Company may, at any time, revise these Terms of Use by updating this page. You are bound by any such revisions and should therefore periodically visit this page to review the then current Terms of Use.

Small Font
Medium Font
Large Font

email

print

Join the OMNARIS Relief is Here Program
Pay Only $11
And pay only $11 every time you fill your prescription.*

*Maximum savings of $50 on up to 12 prescription fills of OMNARIS per year. For qualifying patients. Restrictions apply.
Full Program rules

Considering OMNARIS

24/7 relief for all your nasal allergy symptoms, all year long — that’s comfortable to take!

Find out more

Symptom relief begins within 24-48 hours after the first dose.

OMNARIS (ciclesonide) Nasal Spray is for the treatment of nasal allergy symptoms associated with seasonal allergic rhinitis (seasonal allergies) in adults and children 6 years of age and older, and with perennial allergic rhinitis (year-round allergies) in adults and adolescents 12 and older.

Important Safety Information

Patients using corticosteroid drugs that weaken the immune system are more susceptible to infection and should avoid exposure to chickenpox or measles. If you have tuberculosis, eye herpes, or untreated infections of any kind, speak to your doctor before using OMNARIS. Yeast infections of the nose and throat may occur.

Patients who have recently had an ulcer in the nose, trauma to the nose or nasal surgery should not use OMNARIS until healing has occurred. Rare instances of nasal irritation and eye problems have been reported following the use of nasal steroids. Talk with your doctor if you have a history of eye problems or experience a change in vision.

Patients taking higher doses of a nasal steroid than recommended, or certain other at-risk individuals, may experience symptoms of a hormonal imbalance, including very rarely changes in menstruation, acne, and weight gain. Like all steroid nasal sprays, OMNARIS may cause slowed growth in children. The growth of children using OMNARIS should be monitored routinely by a healthcare professional.

The most common side effects that may occur with OMNARIS are headache, nosebleed, sore throat and ear pain.

The health information contained on this website is provided for educational purposes only and is not intended to replace discussions with a healthcare professional. The product discussed on this site may have different product labeling in different countries. All decisions regarding patient care must be made with a healthcare professional, considering the unique characteristics of the patient.

For more information, please see the OMNARIS Full Prescribing Information and the OMNARIS Patient's Instructions for Use.

OMNARIS is available by prescription. Ask your healthcare professional if OMNARIS is right for you. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The health information contained on this website is provided for educational purposes only and is not intended to replace discussions with a healthcare professional. This site is intended for U.S. residents only. The product discussed on this site may have different product labeling in different countries. All decisions regarding patient care must be made with a healthcare professional, considering the unique characteristics of the patient.

©2010 Sepracor Inc.and SEPRACOR are registered trademarks of Sepracor Inc.

OMNARIS is a registered trademark of Nycomed GmbH, used with permission.

Sepracor

Bookmark & Share